drugset
drugset / Trial / NCT07299825

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

NCT07299825 ↗

Phase 2 Recruiting 40 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates

Timeline

Start
2024-09-20
Primary completion
2027-09-20
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TRASTUZUMAB BOTIDOTIN Unknown 4.8 mg/kg Intravenous

Indications

HER2 positive breast carcinoma